Online inquiry

IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2696MR)

This product GTTS-WQ2696MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets SOST gene. The antibody can be applied in Low bone mineral density research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_025237.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50964
UniProt ID Q9BQB4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ2696MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9848MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ2311MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ14712MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SEG101
GTTS-WQ13269MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ5873MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ8110MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ11057MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ13049MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW